摘要
受体络氨酸激酶c-Met/HGF途径的异常活化与细胞增殖、入侵、代谢,及许多类型肿瘤包括上消化道肿瘤的不良预后有关。c-Met和多信号通路包括肿瘤发生的特性和侵略性表型的相互作用已经获得了大量关注,表明其在癌症治疗中扮演着富有吸引力的靶点角色。最近几年,在具有潜在的临床应用的、有效的c-Met抑制剂的发展上已经做出了很大的努力,其中一个抑制剂,克唑替尼(双重c-Met/ALK抑制剂)最近被批准应用于具有ALK重排的肺癌治疗。然而有几个重要的问题关于克唑替尼潜在的抗癌作用及其在不同肿瘤类型包括上消化道癌症中发挥的可能的治疗作用的分子机制仍然有待回答。这篇综述的目的是为c-Met/HGF通路在癌症方面的关键作用及c-Met抑制剂的临床前或临床研究提供一个综述。越来越多的证据证明了c-Met抑制剂在其他恶性肿瘤上具有治疗潜力,例如胃癌和胰腺癌。但是, c-Met抑制剂活性的决定因素的识别仍然需要进一步的研究,通过分析影响c-Met和平行的癌症前通路的遗传和环境改变;导致抗c-Met药物发生的机制;被选择的患者可能从治疗中获益。这些研究在改善未来的c-Met靶向疗法在上消化道癌症治疗中的抗癌策略的选择性和有效性上是十分必要的。
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
Current Drug Targets
Title:Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Volume: 15 Issue: 14
Author(s): Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan
Affiliation:
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
摘要: Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved in tumorigenic-properties and invasive-phenotype has gained substantial attention, suggesting its role as an intriguing-target for cancer-therapy. In recent years, there have been considerable efforts in the development of effective c-Met inhibitors with potential clinical-applications and one of them, crizotinib (dual c-Met/ALK inhibitor), has recently been approved for lung-cancers with ALKrearrangement. However several important questions remain to be answered on the molecular mechanisms underlying the antitumor effects of crizotinib, as well as on its possible role in the treatment of different tumor types, including uppergastrointestinal- cancers. The aim of this review is to give an overview on critical role of the c-Met/HGF pathway in cancer, and the preclinical/clinical studies on c-Met inhibitors. There are accumulating evidences on therapeutic potential of c-Met inhibitors for the treatment of other malignancies, such as gastric and pancreatic cancers. However, further investigations are needed to identify determinants of the activity of c-Met inhibitors, through the analysis of genetic/ environmental alterations affecting c-Met and parallel pro-cancer pathways; mechanisms result in developing resistance to anti-c-Met agents; and selection of patients that might benefit from therapy. These studies will be essential to improve the selectivity/efficacy of future anticancer strategies of c-Met targeted-therapies in the treatment of upper gastrointestinal- cancers.
Export Options
About this article
Cite this article as:
Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan , Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141107105456
DOI https://dx.doi.org/10.2174/1389450115666141107105456 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Mini-Reviews in Medicinal Chemistry Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis
Current Stem Cell Research & Therapy Intelligent Polyelectrolytes and Gels in Oral Drug Delivery
Current Pharmaceutical Biotechnology Targeting Phospholipase D-mediated Survival Signals in Cancer
Current Signal Transduction Therapy Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry